Determination of etoricoxib in human plasma using automated on-line solid-phase extraction coupled with LC-APCI/MS/MS

Dalmora, Sérgio Luiz; Brum, Larissa Picada; Ferretto, Ricardo Machado; Oliveira, Paulo Renato de; Barth, Thiago; Sangoi, Maximiliano da Silva

doi:10.1590/s0100-40422008000300021

Cited by 10 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dalmora et al developed LC-APCI/MS/MS method [13] for the quantitative analysis of Etoricoxib in human plasma using an automated online solid-phase extraction with a mobile phase mixture consisting of acetonitrile:water (95:5)/10 mM ammonium acetate (pH 4.0), and the linearity was observed as 0.001-5.0 µg/mL. [14] for the determination of Etoricoxib in pharmaceutical dosage forms using toluene:1,4-dioxane:methanol (8.5:1.0:0.5) as mobile phase in the presence of internal standard rofecoxib (UV detection 235 nm).…”

Section: Original Articlementioning

confidence: 99%

Untitled

2023

AJP

View full text Add to dashboard Cite

Introduction:Etoricoxib is also a bipyridine derivative used as a non-steroidal anti-inflammatory drug. A new stability-indicating reverse phase high-performance liquid chromatographic (HPLC) method has been developed for the quantification of Etoricoxib in tablet dosage forms. Materials and Methods: A Shimadzu HPLC system equipped Agilent C18 column was chosen for the chromatographic study with mobile phase formic acid:acetonitrile (52:48) and a flow rate of 0.8 mL/min (UV detection at 247 nm). Results and Discussion: Linearity was obeyed over the concentration range of 0.5-100 µg/mL with a linear regression equation y = 95013× -11970 and a correlation coefficient of 0.9998. The limit of detection and limit of quantification were found to be 0.1557 and 0.4791 µg/mL, respectively. Stress degradation studies were performed, and the method was validated as per the International Council for Harmonisation guidelines. Conclusion: The RP-HPLC method so developed was found to be selective, specific, precise, accurate, robust, and useful for the estimation of Etoricoxib tablets.

show abstract

Section: Original Articlementioning

confidence: 99%

Untitled

2023

AJP

View full text Add to dashboard Cite

show abstract

“…The supernatant was separated for each solution and was analyzed through UV/Vis spectroscopy. The difference in the quantity of ET as well as of MT, before and after addition to CuO nanoparticles, was calculated from analyzing the UV/Vis spectra [59].…”

Section: Samples Preparationmentioning

confidence: 99%

Synthesis of Copper Oxide-Based Nanoformulations of Etoricoxib and Montelukast and Their Evaluation through Analgesic, Anti-Inflammatory, Anti-Pyretic, and Acute Toxicity Activities

et al. 2022

View full text Add to dashboard Cite

Copper oxide nanoparticles (CuO NPs) were synthesized through the coprecipitation method and used as nanocarriers for etoricoxib (selective COX-2 inhibitor drug) and montelukast (leukotriene product inhibitor drug) in combination therapy. The CuO NPs, free drugs, and nanoformulations were investigated through UV/Vis spectroscopy, FTIR spectroscopy, XRD, SEM, and DLS. SEM imaging showed agglomerated nanorods of CuO NPs of about 87 nm size. The CE1, CE2, and CE6 nanoformulations were investigated through DLS, and their particle sizes were 271, 258, and 254 nm, respectively. The nanoformulations were evaluated through in vitro anti-inflammatory activity, in vivo anti-inflammatory activity, in vivo analgesic activity, in vivo anti-pyretic activity, and in vivo acute toxicity activity. In vivo activities were performed on albino mice. BSA denaturation was highly inhibited by CE1, CE2, and CE6 as compared to other nanoformulations in the in vitro anti-inflammatory activity. The in vivo bioactivities showed that low doses (5 mg/kg) of nanoformulations were more potent than high doses (10 and 20 mg/kg) of free drugs in the inhibition of pain, fever, and inflammation. Lastly, CE2 was more potent than that of other nanoformulations.

show abstract

“…Liquid chromatographytandem mass spectrometry was applied to the determination of Etoricoxib [13]. Liquid chromatography has been also applied to determine Etoricoxib in human plasma [14], [15]. An HPLC-MS/MS method for the simultaneous determination of Etoricoxib and its carbon-13 analog from human plasma was also developed [16].…”

Section: B Introductionmentioning

confidence: 99%

HPLC validation and stress degradation behavior of Etoricoxib in tablets dosage form

Alzaghal,

El-Sayed,

Almosallamy

2023

Benha Journal of Applied Sciences

View full text Add to dashboard Cite

Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain, and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxygenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic acid. Effective chromatographic separation method for etoricoxib was achieved using HPLC instrument by Luna C18 -(150X4.6mm, 5μm) column with isocratic elution of the mobile phase consisting of buffer pH 3.5 of 0.01M potassium dihydrogen phosphate (1.36g/L): acetonitrile: methanol (40:15:45 v/v/v). The wavelength of detection was set to be 235 nm (UV detector), and a flow rate of 1.0 ml/min was employed, 10 μl was used as injection volume and the column temperature was maintained at 30°C. A rapid, simple, and selective reversed-phase high-performance liquid chromatographic method was developed and validated for the assay of Etoricoxib i n its pharmaceutical formulation, under these chromatographic conditions, the peak of Etoricoxib was obtained at a retention time about 5.1 min. and run time of about 7.0 minutes. The developed method was validated in terms of accuracy, precision, linearity, limit of detection, and limit of quantitation. The proposed method can be used for the assay of these drugs in dosage form for routine analysis, this has already been applied to different samples, and this is explained in the applications section.

show abstract

Determination of etoricoxib in human plasma using automated on-line solid-phase extraction coupled with LC-APCI/MS/MS

Cited by 10 publications

References 9 publications

Untitled

Untitled

Synthesis of Copper Oxide-Based Nanoformulations of Etoricoxib and Montelukast and Their Evaluation through Analgesic, Anti-Inflammatory, Anti-Pyretic, and Acute Toxicity Activities

HPLC validation and stress degradation behavior of Etoricoxib in tablets dosage form

Contact Info

Product

Resources

About